FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Olson Charles V
(Last) (First) (Middle)
25801 INDUSTRIAL BLVD SUITE B
(Street)
HAYWARD CA 94545
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/05/2016 		3. Issuer Name and Ticker or Trading Symbol
Anthera Pharmaceuticals Inc [ ANTH ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF TECHNOLOGY OFFICER
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 7,963 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy) (1) 05/17/2023 Common Stock 43,750 4.88 D
Stock option (right to buy) (2) 03/25/2024 Common Stock 922 3.3 D
Stock option (right to buy) (3) 07/29/2024 Common Stock 45,000 2.89 D
Stock option (right to buy) (4) 12/30/2024 Common Stock 50,000 1.61 D
Stock option (right to buy) (5) 09/17/2025 Common Stock 50,000 9.48 D
Stock option (right to buy) (6) 01/07/2026 Common Stock 50,000 3.7 D
Explanation of Responses:
1. This stock option vests annually over four years. The vesting commencement date is March 25, 2013. This stock option is fully vested on March 25, 2017 and will expire on May 17, 2023.
2. This stock option is immediately vested on the grant date of March 25, 2014. This stock option will expire on March 25, 2024.
3. This stock option vests monthly over four years. The vesting commencement date is July 1, 2014. This stock option is fully vested on July 1, 2018 and will expire on July 29, 2024.
4. This stock option vests monthly over four years. The vesting commencement date is December 30, 2014. This stock option is fully vested on December 30, 2018 and will expire on December 30, 2024.
5. This stock option vests monthly over four years. The vesting commencement date is December 30, 2014. This stock option is fully vested on December 30, 2018 and will expire on September 17, 2025.
6. This stock option vests monthly over four years. The vesting commencement date is January 7, 2016. This stock option is fully vested on January 7, 2020 and will expire on January 7, 2026.
Remarks:
/s/ Charles V. Olson 01/13/2016
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.